Finanzen von Kyverna Therapeutics Inc (KYTX)KYTXKyverna Therapeutics Inc

Evaluating the bottom line, Kyverna Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -87.24%, provide a clear picture of how effectively KYTX converts its operational activities into shareholder value.

In the context of the broader market, KYTX competes directly with industry leaders such as CABA and VALN. With a market capitalization of $505.26M, it holds a significant position in the sector. When comparing efficiency, KYTX's gross margin of N/A stands against CABA's N/A and VALN's 9.60%. Such benchmarking helps identify whether Kyverna Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Kyverna has shown a 133.15% increase over the past year, indicating strong long-term growth despite current financial losses. The company has a current ratio of 9.06, suggesting good short-term financial health.